Abstract
Many patients are apprehensive about initiating insulin. Worries about injections, hypoglycemia and weight gain as a result of insulin therapy may contribute to their concerns, and consequently pose a challenge to achieving or maintaining optimal glycemic control. Basal insulin replacement has proven to be effective and safe for initiating insulin therapy in Type 2 diabetes. With increasing β-cell dysfunction, the addition of rapid-acting prandial insulin to basal insulin therapy represents the gold standard for physiologic insulin replacement. Insulin detemir's beneficial profile in terms of offering less weight gain and a reduced risk of hypoglycemic episodes compared with neutral protamine Hagedorn insulin makes it an attractive alternative for basal insulin therapy. This review provides a comprehensive update on the pharmacology, clinical efficacy and safety of insulin detemir in Type 1 and 2 diabetes.
Original language | English (US) |
---|---|
Pages (from-to) | 513-529 |
Number of pages | 17 |
Journal | Therapy |
Volume | 5 |
Issue number | 4 |
DOIs | |
State | Published - 2008 |
Keywords
- Basal insulin
- Insulin detemir
- Insulin glargine
- NPH insulin
- Type 1 diabetes
- Type 2 diabetes
ASJC Scopus subject areas
- Pharmacology (medical)